Aptose Biosciences Faces Delisting Concerns
Ticker: APTOF · Form: 8-K · Filed: Jan 21, 2025 · CIK: 882361
| Field | Detail |
|---|---|
| Company | Aptose Biosciences INC. (APTOF) |
| Form Type | 8-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, corporate-actions
TL;DR
Aptose might be delisted - big trouble for shareholders.
AI Summary
Aptose Biosciences Inc. filed an 8-K on January 21, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing. The report was filed as of January 14, 2025. The company was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
Why It Matters
This filing indicates potential issues with Aptose Biosciences' continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards suggests significant financial or operational distress for the company.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- January 14, 2025 (date) — Date of earliest event reported
- January 21, 2025 (date) — Filing date
FAQ
What specific listing rule or standard has Aptose Biosciences Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Aptose Biosciences Inc. has failed to satisfy, only that it is a notice of delisting or failure to satisfy a continued listing rule or standard.
What is the reason for the potential transfer of listing mentioned in the filing?
The filing states 'Transfer of Listing' as an item of information, but does not provide the specific reasons or destination for any such transfer.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 14, 2025.
What were Aptose Biosciences Inc.'s previous names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. (name change on September 5, 2014) and prior to that, Imutec Pharma Inc. (name change on January 13, 1997).
What is the SIC code for Aptose Biosciences Inc.?
The Standard Industrial Classification (SIC) code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 627 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2025-01-21 17:21:00
Key Financial Figures
- $1.00 — mmon shares have been below the minimum $1.00 per share required for continued listin
Filing Documents
- d877128d8k.htm (8-K) — 24KB
- 0001193125-25-009627.txt ( ) — 150KB
- apto-20250114.xsd (EX-101.SCH) — 3KB
- apto-20250114_lab.xml (EX-101.LAB) — 19KB
- apto-20250114_pre.xml (EX-101.PRE) — 12KB
- d877128d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit No. Description of Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 21, 2025 APTOSE BIOSCIENCES INC. By: /s/ Fletcher Payne Name: Fletcher Payne Title: Senior Vice President and Chief Financial Officer